En español

Targeted Mutagenesis Resources

Revised September 2012

  • Fred Hutchison Cancer Research Center
    Gene Trap Mutagenesis We are using gene traps in embryonic stem (ES) cells to identify genes regulated by growth factors. We have begun large scale sequencing of ES cell clones and sequence tags are deposited to NCBI's dbGSS .  Sequence searches for genes that we have trapped can be performed by running a BLAST search of the dbGSS database.  A list of the genes we have trapped can be found in our gene trap database.
  • Manitoba Institute of Cell Biology, Centre for Mammalian Functional Genomics
    We have developed a process called Tagged-Sequence Mutagenesis to disrupt genes expressed in mouse embryo-derived stem (ES) cells and to characterize each mutation by direct DNA sequencing. Comparison of these sequence tags (PSTs) with the existing databases identifies disruptions of known genes or genes which may be related by homology or functional domains. The ability to induce, characterize and maintain mutations in ES cells circumvents many limitations associated with conventional mammalian genetics, and will greatly increase the number of mutant alleles (typically loss of function mutations) by which gene functions can be studied in mice and in cell lines derived from such mice.
  • Gene trap Consortium
    A public resource of insertional mutations in mouse embryonic stem cells
  • Centre For Modelling Human Disease Gene Trap Core, University of Toronto/Mount Sinai Hospital
    The Gene Trap Laboratory is a core facility of The Centre for Modeling Human Disease. A database of in vitro expression patterns can now be searched.
  • Induced Mutant Resource
    Genetically engineered and induced mutation mouse models for research
  • Lexicon Genetics Corp.
    Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We use proprietary gene knockout technology to systematically discover the physiological functions of genes in mice and to identify which corresponding human genes encode potential targets for therapeutic intervention, or drug targets.
  • Deltagen
    Deltagen's unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology , systematic array analysis and cell-based array analysis capabilities enable us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed
  • Velocigene/Regeneron
    Regeneron's Velocigene™ allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA. In producing knock-out models, a color or fluorescent marker is substituted in place of the actual gene sequence, allowing for high-resolution visualization of precisely where the gene is active in the body, during normal body functioning, as well as in disease processes. Velocigene uses automated systems for most steps in the process. Thus, Velocigene allows scientists to identify rapidly the physical and biological effects of deleting or over-expressing the target gene
  • Mouse Knockout & Mutation Database
    Fully searchable database of phenotypic information related to knockouts and classical mutations in mice , includingextensive links to MEDLINE on BioMedNet
  • Deltabase
    DeltaBase is a comprehensive, fully featured searchable database of in vivo -derived mammalian gene function information and gene targets. Built upon our high-throughput mouse gene knockout technology and standardized phenotypic analysis protocols, this cutting-edge tool can be used in the pharmaceutical and biotechnology industries to identify drug targets, validate the therapeutic potential of specific genes and accelerate the drug discovery process. DeltaBase currently is licensed by nonexclusive agreement to such leading global pharmaceutical companies as Pfizer, GlaxoSmithKline and Merck.

This page was last updated September 2012